Patients after the Fontan operation at a single institution will be randomized to receive a
standardized extract of Aesculus hippocastanum L. (horse chestnut) or placebo for 4 months in
a crossover clinical trial. The primary outcome will be the mesenteric artery resistance
measured by Dopple sonography.